ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 63 Shown
  • Management of Patients With Localized Follicular Lymphoma

    Farrukh Awan MD, MS - 7/29/2015
    I provide insights and discuss the current state of management for patients with localized follicular lymphoma.
  • Anti-CD20 Antibodies in CLL: What to Do in Regular Practice

    John M. Burke MD - 7/9/2015
    How I select between available anti-CD20 antibodies for patients with CLL.
  • How Can We Further Improve Outcomes in Acute Promyelocytic Leukemia?

    Farhad Ravandi MD - 6/18/2015 1 comment / Last Comment: 6/29/2015
    Farhad Ravandi, MD, provides insight as to how he manages acute promyelocytic leukemia cases.
  • The CLL Treatment Revolution

    Jeff P. Sharman MD - 5/26/2015
    Expert insight on treatment selection for patients with relapsed chronic lymphocytic leukemia.
  • Targeted Therapy for Indolent Lymphomas: Where We Are and Where We Are Heading

    Steven M. Horwitz MD - 5/26/2015 1 comment / Last Comment: 6/15/2015
    How do recent advances in targeted therapies affect patients with less common forms of indolent non-Hodgkin’s lymphoma?
  • A CML Patient With Elevated BCR-ABL at 3 Months: To Switch or Not to Switch?

    Elias Jabbour MD - 4/27/2015 3 comments / Last Comment: 6/16/2015
    Knowing when to switch treatment based on BCR-ABL levels is key to effective CML therapy.
  • Utility of Kinase Inhibitors in the Management of Relapsed CLL

    Farrukh Awan MD, MS - 4/27/2015 1 comment / Last Comment: 5/19/2015
    Have you integrated recently approved kinase inhibitors into your management strategies for patients with relapsed CLL?
  • Acute Myeloid Leukemia: Will Understanding the Biology Lead to Better Outcomes?

    Farhad Ravandi MD - 3/26/2015 3 comments / Last Comment: 6/29/2015
    New therapeutic targets are beginning to offer improved strategies for AML treatment.
  • Ibrutinib and the Management of Patients With del(17p) CLL

    Farrukh Awan MD, MS - 3/23/2015 1 comment / Last Comment: 4/7/2015
    How ibrutinib earned its place among first-line treatment options for patients with CLL and del(17p)
  • How I Treat My Patients With CLL Who Are Fit or Otherwise Healthy

    Jeff P. Sharman MD - 3/11/2015 4 comments / Last Comment: 6/30/2015
    Chemotherapy or novel agents for initial treatment of CLL? Learn how to best apply new molecular markers to individualize treatment for your patients who are fit or otherwise healthy.
10 of 63 Shown
Show 10 More
Loading...